Conclusion
Mesdopetam was safe and well tolerated in healthy male volunteers. Pharmacokinetic analysis indicated rapid absorption and dose-linear pharmacokinetics of mesdopetam, with a plasma half-life around 7 hours, upon single and repeated dosing. The pharmacokinetics of mesdopetam supports twice daily use in patients.